Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response

Virology

Volumn 398, Issue 1, 2010, Pages 115-124

  Bosch, Katherine A ^a,b   Rainwater, Stephanie ^a   Jaoko, Walter ^c   Overbaugh, Julie ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NAIROBI   (Kenya)

Author keywords

Antibody escape; Broad neutralizing antibody response; Envelope sequence evolution; HIV 1

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; PROLINE;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; GENE SEQUENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS ENVELOPE; VIRUS GENE; VIRUS ISOLATION;

ADULT; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; CLONING, MOLECULAR; FEMALE; GENE EXPRESSION REGULATION, VIRAL; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; PHYLOGENY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 75849146082     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.11.032     Document Type: Article

References (54)

1. Albert J., Naucler A., Bottiger B., Broliden P.A., Albino P., Ouattara S.A., Bjorkegren C., Valentin A., Biberfeld G., and Fenyo E.M. Replicative capacity of HIV-2, like HIV-1, correlates with severity of immunodeficiency. AIDS 4 4 (1990) 291-295
2. Blish C.A., Nedellec R., Mandaliya K., Mosier D.E., and Overbaugh J. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 21 6 (2007) 693-702
3. Blish C.A., Jalalian-Lechak Z., Rainwater S., Nguyen M.A., Dogan O.C., and Overbaugh J. Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D HIV-1 envelope variants. J. Virol. 83 15 (2009) 7783-7788
4. Burton D.R., Stanfield R.L., and Wilson I.A. Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U. S. A. 102 42 (2005) 14943-14948
5. Chackerian B., Rudensey L., and Overbaugh J. Specific N-linked and O-linked glycosylation additions in the envelope V1 domain of SIV variants that evolve in the host alter neutralizing antibody recognition. J. Virol. 71 10 (1997) 7719-7727
6. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T.C., Kuo Y.H., Brookmeyer R., Zeiger M.A., Barditch-Crovo P., and Siliciano R.F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387 6629 (1997) 183-188
7. Deeks S.G., Schweighardt B., Wrin T., Galovich J., Hoh R., Sinclair E., Hunt P., McCune J.M., Martin J.N., Petropoulos C.J., and Hecht F.M. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J. Virol. 80 12 (2006) 6155-6164
8. Dhillon A.K., Donners H., Pantophlet R., Johnson W.E., Decker J.M., Shaw G.M., Lee F.H., Richman D.D., Doms R.W., Vanham G., and Burton D.R. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 81 12 (2007) 6548-6562
9. Dickover R., Garratty E., Yusim K., Miller C., Korber B., and Bryson Y. Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J. Virol. 80 13 (2006) 6525-6533
10. Doria-Rose N.A., Learn G.H., Rodrigo A.G., Nickle D.C., Li F., Mahalanabis M., Hensel M.T., McLaughlin S., Edmonson P.F., Montefiori D., Barnett S.W., Haigwood N.L., and Mullins J.I. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J. Virol. 79 17 (2005) 11214-11224
11. Edwards T.G., Hoffman T.L., Baribaud F., Wyss S., LaBranche C.C., Romano J., Adkinson J., Sharron M., Hoxie J.A., and Doms R.W. Relationships between CD4 independence, neutralization sensitivity, and exposure of a CD4-induced epitope in a human immunodeficiency virus type 1 envelope protein. J. Virol. 75 11 (2001) 5230-5239
12. Gray E.S., Moore P.L., Choge I.A., Decker J.M., Bibollet-Ruche F., Li H., Leseka N., Treurnicht F., Mlisana K., Shaw G.M., Karim S.S., Williamson C., and Morris L. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81 12 (2007) 6187-6196
13. Groenink M., Fouchier R.A., Broersen S., Baker C.H., Koot M., van't Wout A.B., Huisman H.G., Miedema F., Tersmette M., and Schuitemaker H. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 260 5113 (1993) 1513-1516
14. Kimata J.T., Kuller L., Anderson D.B., Dailey P., and Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 5 5 (1999) 535-541
15. Kimura M. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J. Mol. Evol. 16 2 (1980) 111-120
16. Kolchinsky P., Kiprilov E., Bartley P., Rubinstein R., and Sodroski J. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J. Virol. 75 7 (2001) 3435-3443
17. Kolchinsky P., Kiprilov E., and Sodroski J. Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J. Virol. 75 5 (2001) 2041-2050
18. Lavreys L., Baeten J.M., Kreiss J.K., Richardson B.A., Chohan B.H., Hassan W., Panteleeff D.D., Mandaliya K., Ndinya-Achola J.O., and Overbaugh J. Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women. J. Infect. Dis. 189 2 (2004) 303-311
19. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 16 (2005) 10108-10125
20. Li B., Decker J.M., Johnson R.W., Bibollet-Ruche F., Wei X., Mulenga J., Allen S., Hunter E., Hahn B.H., Shaw G.M., Blackwell J.L., and Derdeyn C.A. Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J. Virol. 80 11 (2006) 5211-5218
21. Li M., Salazar-Gonzalez J.F., Derdeyn C.A., Morris L., Williamson C., Robinson J.E., Decker J.M., Li Y., Salazar M.G., Polonis V.R., Mlisana K., Karim S.A., Hong K., Greene K.M., Bilska M., Zhou J., Allen S., Chomba E., Mulenga J., Vwalika C., Gao F., Zhang M., Korber B.T., Hunter E., Hahn B.H., and Montefiori D.C. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J. Virol. 80 23 (2006) 11776-11790
22. Li Y., Migueles S.A., Welcher B., Svehla K., Phogat A., Louder M.K., Wu X., Shaw G.M., Connors M., Wyatt R.T., and Mascola J.R. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13 9 (2007) 1032-1034
23. Li Y., Cleveland B., Klots I., Travis B., Richardson B.A., Anderson D., Montefiori D., Polacino P., and Hu S.L. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 82 2 (2008) 638-651
24. Long E.M., Rainwater S.M., Lavreys L., Mandaliya K., and Overbaugh J. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res. Hum. Retrovir. 18 8 (2002) 567-576
25. Mahalanabis M., Jayaraman P., Miura T., Pereyra F., Chester E.M., Richardson B., Walker B., and Haigwood N.L. Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J. Virol. 83 2 (2009) 662-672
26. Markowitz M., Louie M., Hurley A., Sun E., Di Mascio M., Perelson A.S., and Ho D.D. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 77 8 (2003) 263-277
27. Martin H.L., Jackson D.J., Mandaliya K., Bwayo J., Rakwar J.P., Nyange P., Moses S., Ndinya-Achola J.O., Holmes K., Plummer F., Ngugi E., and Kreiss J. Preparation for AIDS vaccine evaluation in Mombasa, Kenya: establishment of seronegative cohorts of commercial sex workers and trucking company employees. AIDS Res. Hum. Retrovir. 10 Suppl. 2 (1994) S235-S237
28. Moore P.L., Ranchobe N., Lambson B.E., Gray E.S., Cave E., Abrahams M.R., Bandawe G., Mlisana K., Abdool Karim S.S., Williamson C., and Morris L. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 5 9 (2009) e1000598
29. Neilson J.R., John G.C., Carr J.K., Lewis P., Kreiss J.K., Jackson S., Nduati R.W., Mbori-Ngacha D., Panteleeff D.D., Bodrug S., Giachetti C., Bott M.A., Richardson B.A., Bwayo J., Ndinya-Achola J., and Overbaugh J. Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J. Virol. 73 5 (1999) 4393-4403
30. Ogert R.A., Lee M.K., Ross W., Buckler-White A., Martin M.A., and Cho M.W. N-linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dual tropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism. J. Virol. 75 13 (2001) 5998-6006
31. Overbaugh J., Rudensey L.M., Papenhausen M.D., Benveniste R.E., and Morton W.R. Variation in simian immunodeficiency virus env is confined to V1 and V4 during progression to simian AIDS. J. Virol. 65 12 (1991) 7025-7031
32. Perelson A.S., Neumann A.U., Markowitz M., Leonard J.M., and Ho D.D. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271 5255 (1996) 1582-1586
33. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A., Saksela K., Markowitz M., and Ho D.D. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387 6629 (1997) 188-191
34. Piantadosi A., Panteleeff D., Blish C.A., Baeten J.M., Jaoko W., McClelland R.S., and Overbaugh J. HIV-1 neutralizing antibody breadth is affected by factors early in infection, but does not influence disease progression. J. Virol. 83 19 (2009) 10269-10274
35. Rainwater S., Devange S., Sagar M., Ndinya-Achola J., Mandaliya K., Kreiss J.K., and Overbaugh J. No evidence for rapid subtype C spread within an epidemic in which multiple subtypes and intersubtype recombinants circulate. AIDS Res. Hum. Retrovir. 21 12 (2005) 1060-1065
36. Rainwater S.M., Wu X., Nduati R., Nedellec R., Mosier D., John-Stewart G., Mbori-Ngacha D., and Overbaugh J. Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. Curr. HIV Res. 5 2 (2007) 189-197
37. Rangel H.R., Weber J., Chakraborty B., Gutierrez A., Marotta M.L., Mirza M., Kiser P., Martinez M.A., Este J.A., and Quinones-Mateu M.E. Role of the human immunodeficiency virus type 1 envelope gene in viral fitness. J. Virol. 77 16 (2003) 9069-9073
38. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100 7 (2003) 4144-4149
39. Rong R., Gnanakaran S., Decker J.M., Bibollet-Ruche F., Taylor J., Sfakianos J.N., Mokili J.L., Muldoon M., Mulenga J., Allen S., Hahn B.H., Shaw G.M., Blackwell J.L., Korber B.T., Hunter E., and Derdeyn C.A. Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1. J. Virol. 81 11 (2007) 5658-5668
40. Rong R., Li B., Lynch R.M., Haaland R.E., Murphy M.K., Mulenga J., Allen S.A., Pinter A., Shaw G.M., Hunter E., Robinson J.E., Gnanakaran S., and Derdeyn C.A. Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog. 5 9 (2009) e1000594
41. Rousseau C.M., Nduati R.W., Richardson B.A., John-Stewart G.C., Mbori-Ngacha D.A., Kreiss J.K., and Overbaugh J. Association of levels of HIV-1-infected breast milk cells and risk of mother-to-child transmission. J. Infect. Dis. 190 10 (2004) 1880-1888
42. Rudensey L.M., Papenhausen M.D., and Overbaugh J. Replication and persistence of simian immunodeficiency virus variants after passage in macaque lymphocytes and established human cell lines. J. Virol. 67 3 (1993) 1727-1733
43. Sagar M., Wu X., Lee S., and Overbaugh J. Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80 19 (2006) 9586-9598
44. Saitou N., and Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4 (1987) 406-425
45. Scheid J.F., Mouquet H., Feldhahn N., Seaman M.S., Velinzon K., Pietzsch J., Ott R.G., Anthony R.M., Zebroski H., Hurley A., Phogat A., Chakrabarti B., Li Y., Connors M., Pereyra F., Walker B.D., Wardemann H., Ho D., Wyatt R.T., Mascola J.R., Ravetch J.V., and Nussenzweig M.C. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458 7238 (2009) 636-640
46. Skrabal K., Saragosti S., Labernardiere J.L., Barin F., Clavel F., and Mammano F. Human immunodeficiency virus type 1 variants isolated from single plasma samples display a wide spectrum of neutralization sensitivity. J. Virol. 79 18 (2005) 11848-11857
47. Sullivan N., Thali M., Furman C., Ho D.D., and Sodroski J. Effect of amino acid changes in the V1/V2 region of the human immunodeficiency virus type 1 gp120 glycoprotein on subunit association, syncytium formation, and recognition by a neutralizing antibody. J. Virol. 67 6 (1993) 3674-3679
48. Thompson J.D., Gibson T.J., Plewniak F., Jeanmougin F., and Higgins D.G. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25 24 (1997) 4876-4882
49. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., Lehrman J.K., Priddy F.H., Olsen O.A., Frey S.M., Hammond P.W., Miiro G., Serwanga J., Pozniak A., McPhee D., Manigart O., Mwananyanda L., Karita E., Inwoley A., Jaoko W., Dehovitz J., Bekker L.G., Pitisuttithum P., Paris R., Allen S., Kaminsky S., Zamb T., Moyle M., Koff W.C., Poignard P., and Burton D.R. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326 (2009) 285-289
50. Wei X., Decker J.M., Liu H., Zhang Z., Arani R.B., Kilby J.M., Saag M.S., Wu X., Shaw G.M., and Kappes J.C. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46 6 (2002) 1896-1905
51. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 6929 (2003) 307-312
52. Wu X., Parast A.B., Richardson B.A., Nduati R., John-Stewart G., Mbori-Ngacha D., Rainwater S.M., and Overbaugh J. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J. Virol. 80 2 (2006) 835-844
53. Zhang P.F., Bouma P., Park E.J., Margolick J.B., Robinson J.E., Zolla-Pazner S., Flora M.N., and Quinnan Jr. G.V. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J. Virol. 76 2 (2002) 644-655
54. Zhang P.F., Cham F., Dong M., Choudhary A., Bouma P., Zhang Z., Shao Y., Feng Y.R., Wang L., Mathy N., Voss G., Broder C.C., and Quinnan Jr. G.V. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc. Natl. Acad. Sci. U. S. A. 104 24 (2007) 10193-10198